Bladder, Kidney and Genitals
-
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Read the plain language summary of an analysis of the PROSPER study looking at whether patient traits affect survival in people with advanced prostate cancer who are treated with enzalutamide compared to placebo.
-
Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
This plain language summary provides an overview of a real-world study involving men with advanced prostate cancer using medical information from the Veterans Health Administration.
-
Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment
The new plain language summary of publication in Future Cardiology uses information from the Fabry Registry to understand the effects of agalsidase beta treatment in women with Fabry disease.
-
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer
Read about the ongoing TALAPRO-2 study looking at the combination of talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer.
-
A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder
In this plain language summary published in Journal of Comparative Effectiveness Research, learn about a study that looked at how likely it is that individual people with overactive bladder will achieve a certain level of improvement in their symptoms when taking fesoterodine.
-
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial
Summary and patient perspectives of the ARASENS trial looking at treatment with darolutamide compared to placebo in combination with docetaxel and androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.
-
Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer
This is plain language summary provides an overview of the HERO study looking at how well relugolix works, compared with leuprolide, in men with advanced prostate cancer.
-
Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial
The latest plain language summary of publication (PLSP) published in Future Oncology provides a summary of the ARAMIS trial.